smurf1-inhibitor-1

AC430 is a potent and specific small molecule inhibitor of janus kinase 2 (JAK2), which has been implicated as a target for therapy in both oncology and autoimmune disease. AC430 is currently being developed by Ambit. In preclinical studies, AC430 has exhibited potency against JAK2 and V617F mutated JAK2 in cell-based models that is at least equivalent to, and in most cases superior to, competing JAK2 inhibitors. In preclinical oncology and autoimmune models, AC430 is well tolerated and has significant efficacy at oral doses as low as 10 mg kg day.

Smurf1 inhibitor 1 is a inhibitor that promotes bone formation.

Smurf1-IN-A01 (A01) is a ubiquitin ligase Smad ubiquitination regulatory factor-1 inhibitor (Kd: 3.664 nM) that enhances BMP-2 responsiveness by preventing Smurf1-mediated Smad1 5 degradation.

1-ethyl-6-fluoro-4-oxo-7-[4-(3-phenylpropanoyl)piperazin-1-yl]-1,4-dihydroquinoline-3-carboxylic acid is a compound used as a molecular structural unit and is a SMURF1 inhibitor.

Smurf1-IN-1, a selective E3 ubiquitin protein ligase 1 (SMURF1) inhibitor, exhibits oral activity with an IC50 of 92 nM and demonstrates considerable efficacy in a rat model of pulmonary hypertension [1].